Is it really possible to cure hairy cell leukemia patients only with frontline therapy?

Pier Luigi Zinzani, Vittorio Stefoni, Alessandro Broccoli, Cinzia Pellegrini, Letizia Gandolfi, Beatrice Casadei, Roberto Maglie, Stefano Pileri, Lisa Argnani

Research output: Contribution to journalArticle

Abstract

Hairy cell leukemia (HCL) patients could have an excellent prognosis with adequate treatment. Treatments are not generally curative but are extremely effective in inducing long-lasting clinical remissions. An observational retrospective study was conducted on a single-center registry of 144 patients with a median follow-up of 11.5 years, focusing on long-lasting continuous first complete remissions (CR) wondering if patients can be cured only with front-line approach. CR for more than 5 years after first-line therapy were found in 22.2 % cases. The median duration of response was 9.8 years, while for relapsed patients, the first response had a median duration of 2.4 years. Three different subsets of long-lasting first CR were identified: 15 patients are between 5 and 10 years with a median duration of CR of 6.5 years; 7 patients are between 10 and 15 years with a median duration of CR of 12.3 years; and 10 patients present a follow-up superior to 15 years with a median duration of CR of 20.0 years. There is a need for continuous study in this field to better define the optimal therapeutic regimen and, in particular, the biological issues since at least 20-25 % of HCL patients can be cured with only one treatment.

Original languageEnglish
Pages (from-to)1565-1569
Number of pages5
JournalAnnals of Hematology
Volume93
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Hairy Cell Leukemia
Therapeutics
Observational Studies
Registries
Retrospective Studies

Keywords

  • Continuous complete response
  • First-line therapy
  • Hairy cell leukemia
  • New drugs
  • Purine analogs

ASJC Scopus subject areas

  • Hematology

Cite this

Zinzani, P. L., Stefoni, V., Broccoli, A., Pellegrini, C., Gandolfi, L., Casadei, B., ... Argnani, L. (2014). Is it really possible to cure hairy cell leukemia patients only with frontline therapy? Annals of Hematology, 93(9), 1565-1569. https://doi.org/10.1007/s00277-014-2081-5

Is it really possible to cure hairy cell leukemia patients only with frontline therapy? / Zinzani, Pier Luigi; Stefoni, Vittorio; Broccoli, Alessandro; Pellegrini, Cinzia; Gandolfi, Letizia; Casadei, Beatrice; Maglie, Roberto; Pileri, Stefano; Argnani, Lisa.

In: Annals of Hematology, Vol. 93, No. 9, 2014, p. 1565-1569.

Research output: Contribution to journalArticle

Zinzani, PL, Stefoni, V, Broccoli, A, Pellegrini, C, Gandolfi, L, Casadei, B, Maglie, R, Pileri, S & Argnani, L 2014, 'Is it really possible to cure hairy cell leukemia patients only with frontline therapy?', Annals of Hematology, vol. 93, no. 9, pp. 1565-1569. https://doi.org/10.1007/s00277-014-2081-5
Zinzani PL, Stefoni V, Broccoli A, Pellegrini C, Gandolfi L, Casadei B et al. Is it really possible to cure hairy cell leukemia patients only with frontline therapy? Annals of Hematology. 2014;93(9):1565-1569. https://doi.org/10.1007/s00277-014-2081-5
Zinzani, Pier Luigi ; Stefoni, Vittorio ; Broccoli, Alessandro ; Pellegrini, Cinzia ; Gandolfi, Letizia ; Casadei, Beatrice ; Maglie, Roberto ; Pileri, Stefano ; Argnani, Lisa. / Is it really possible to cure hairy cell leukemia patients only with frontline therapy?. In: Annals of Hematology. 2014 ; Vol. 93, No. 9. pp. 1565-1569.
@article{180eb5b016b749e6a0e9f85f39b4e4a9,
title = "Is it really possible to cure hairy cell leukemia patients only with frontline therapy?",
abstract = "Hairy cell leukemia (HCL) patients could have an excellent prognosis with adequate treatment. Treatments are not generally curative but are extremely effective in inducing long-lasting clinical remissions. An observational retrospective study was conducted on a single-center registry of 144 patients with a median follow-up of 11.5 years, focusing on long-lasting continuous first complete remissions (CR) wondering if patients can be cured only with front-line approach. CR for more than 5 years after first-line therapy were found in 22.2 {\%} cases. The median duration of response was 9.8 years, while for relapsed patients, the first response had a median duration of 2.4 years. Three different subsets of long-lasting first CR were identified: 15 patients are between 5 and 10 years with a median duration of CR of 6.5 years; 7 patients are between 10 and 15 years with a median duration of CR of 12.3 years; and 10 patients present a follow-up superior to 15 years with a median duration of CR of 20.0 years. There is a need for continuous study in this field to better define the optimal therapeutic regimen and, in particular, the biological issues since at least 20-25 {\%} of HCL patients can be cured with only one treatment.",
keywords = "Continuous complete response, First-line therapy, Hairy cell leukemia, New drugs, Purine analogs",
author = "Zinzani, {Pier Luigi} and Vittorio Stefoni and Alessandro Broccoli and Cinzia Pellegrini and Letizia Gandolfi and Beatrice Casadei and Roberto Maglie and Stefano Pileri and Lisa Argnani",
year = "2014",
doi = "10.1007/s00277-014-2081-5",
language = "English",
volume = "93",
pages = "1565--1569",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Is it really possible to cure hairy cell leukemia patients only with frontline therapy?

AU - Zinzani, Pier Luigi

AU - Stefoni, Vittorio

AU - Broccoli, Alessandro

AU - Pellegrini, Cinzia

AU - Gandolfi, Letizia

AU - Casadei, Beatrice

AU - Maglie, Roberto

AU - Pileri, Stefano

AU - Argnani, Lisa

PY - 2014

Y1 - 2014

N2 - Hairy cell leukemia (HCL) patients could have an excellent prognosis with adequate treatment. Treatments are not generally curative but are extremely effective in inducing long-lasting clinical remissions. An observational retrospective study was conducted on a single-center registry of 144 patients with a median follow-up of 11.5 years, focusing on long-lasting continuous first complete remissions (CR) wondering if patients can be cured only with front-line approach. CR for more than 5 years after first-line therapy were found in 22.2 % cases. The median duration of response was 9.8 years, while for relapsed patients, the first response had a median duration of 2.4 years. Three different subsets of long-lasting first CR were identified: 15 patients are between 5 and 10 years with a median duration of CR of 6.5 years; 7 patients are between 10 and 15 years with a median duration of CR of 12.3 years; and 10 patients present a follow-up superior to 15 years with a median duration of CR of 20.0 years. There is a need for continuous study in this field to better define the optimal therapeutic regimen and, in particular, the biological issues since at least 20-25 % of HCL patients can be cured with only one treatment.

AB - Hairy cell leukemia (HCL) patients could have an excellent prognosis with adequate treatment. Treatments are not generally curative but are extremely effective in inducing long-lasting clinical remissions. An observational retrospective study was conducted on a single-center registry of 144 patients with a median follow-up of 11.5 years, focusing on long-lasting continuous first complete remissions (CR) wondering if patients can be cured only with front-line approach. CR for more than 5 years after first-line therapy were found in 22.2 % cases. The median duration of response was 9.8 years, while for relapsed patients, the first response had a median duration of 2.4 years. Three different subsets of long-lasting first CR were identified: 15 patients are between 5 and 10 years with a median duration of CR of 6.5 years; 7 patients are between 10 and 15 years with a median duration of CR of 12.3 years; and 10 patients present a follow-up superior to 15 years with a median duration of CR of 20.0 years. There is a need for continuous study in this field to better define the optimal therapeutic regimen and, in particular, the biological issues since at least 20-25 % of HCL patients can be cured with only one treatment.

KW - Continuous complete response

KW - First-line therapy

KW - Hairy cell leukemia

KW - New drugs

KW - Purine analogs

UR - http://www.scopus.com/inward/record.url?scp=84905565640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905565640&partnerID=8YFLogxK

U2 - 10.1007/s00277-014-2081-5

DO - 10.1007/s00277-014-2081-5

M3 - Article

C2 - 24752417

AN - SCOPUS:84905565640

VL - 93

SP - 1565

EP - 1569

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 9

ER -